Genentech Singapore To Buy Local Lonza Plant To Produce Avastin
This article was originally published in PharmAsia News
Executive SummarySingapore's Roche subsidiary, Genentech Singapore, plans to buy Lonza Biologics Singapore's cell-culture plant by exercising an option. Roche plans to merge the facility, bought at a cost of $201 million and up to $48.5 million in milestone payments, with Genentech Singapore's separate facility. Roche expects to produce its Avastin (bevacizumab) in bulk for treating several types of cancer. The merger of facilities is to include about 230 Lonza employees to raise the work force at Genentech Singapore to 325. (Click here for more
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”